Výsledky vyhledávání - "D. Bradley Woodward"

GLP-1 receptor agonists, CKD, and eGFR trajectory - Authors' reply

Autor: Mark Lakshmanan, Brian Rayner, D. Bradley Woodward, Robert S. Busch, Fady T. Botros, Alan G. Zimmermann, Katherine R. Tuttle

Publikováno v: The lancet. Diabetesendocrinology. 6(10)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9a2a0b59738050b58d0d445e8463704
https://pubmed.ncbi.nlm.nih.gov/30266180

Zobrazit plný text záznamu

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Autor: Katherine R. Tuttle, Robert S. Busch, Brian Rayner, Fady T. Botros, D. Bradley Woodward, Alan G. Zimmermann, Mark Lakshmanan

Publikováno v: The lancet. Diabetesendocrinology. 6(8)

Summary Background Many antihyperglycaemic drugs, including insulin, are primarily cleared by the kidneys, restricting treatment options for patients with kidney disease. Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist that is n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57a774a1949c2a0fc6d1a1427a75828a
https://pubmed.ncbi.nlm.nih.gov/30266182

Zobrazit plný text záznamu

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

Autor: Francisco J. Tinahones, Juan P. Frias, Honghua Jiang, Luis-Emilio Garcia-Perez, Zvonko Milicevic, Julio Wainstein, D. Bradley Woodward, Kenneth E. Robertson, Bernhard Ludvik

Publikováno v: The lancet. Diabetesendocrinology. 6(5)

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors improve glycaemic control and reduce bodyweight in patients with type 2 diabetes through different mechanisms. We assessed the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98bc6b8a2e50aeaa553a9cad2fcb51df
https://pubmed.ncbi.nlm.nih.gov/29803266

Zobrazit plný text záznamu

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

Autor: Honghua Jiang, Tibor Ivanyi, Zvonko Milicevic, Paolo Pozzilli, D. Bradley Woodward, Melanie J. Davies, Esteban Jódar, Paul Norwood

Publikováno v: ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)

Aim: To compare the addition of weekly dulaglutide vs the addition of placebo to titrated glargine in patients with type 2 diabetes (T2D) with sub‐optimum glycated haemoglobin (HbA1c) concentration. Materials and Methods: Patients (N = 300) from th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb860e15a9a9b63f019cdaef31d2dddf
https://pubmed.ncbi.nlm.nih.gov/28294499

Zobrazit plný text záznamu

Troponin-I as a prognosticator of mortality in severe sepsis patients

Autor: Yanping Wang, Jijo John, Darell Heiselman, Diana Fisher, S. Betty Yan, Gary T. Kinasewitz, D. Bradley Woodward

Publikováno v: Journal of Critical Care. 25:270-275

Purpose: The purpose of this retrospective study was to evaluate cardiac troponin-I (cTnI) as a 28-day mortality prognosticator and predictor for a drotrecogin alfa (activated) (DrotAA) survival benefit in recombinant human activated Protein C Worldw

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1e2d9ad66fd7c406465a5304c59a947
https://doi.org/10.1016/j.jcrc.2009.12.001

Zobrazit plný text záznamu

Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*

Autor: Mary A Short, Heidi J. Dalton, Joseph A. Carcillo, D. Bradley Woodward, Mark D. Williams

Publikováno v: Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 13(6)

REsearching severe Sepsis and Organ dysfunction in children: A gLobal perspective (RESOLVE), a phase III trial of drotrecogin alfa (activated) in pediatric severe sepsis, examined biomarker changes in inflammation and coagulation. This report describ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6cffc8be1c84d1a735ec9d21b26c4bd
https://pubmed.ncbi.nlm.nih.gov/23128590

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání